- Home
- FLC vs SKYE Comparison
FLC vs SKYE Comparison
Compare FLC & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLC | SKYE |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.0M | 29.1M |
| IPO Year | 2003 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FLC | SKYE |
|---|---|---|
| Price | $16.71 | $0.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 21.4K | ★ 175.2K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.89 | $0.57 |
| 52 Week High | $18.09 | $5.75 |
Technical Indicators
Market Signals| Indicator | FLC | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 43.27 |
| Support Level | $16.26 | $0.71 |
| Resistance Level | $17.41 | $0.83 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 69.34 | 23.69 |
Price Performance
Historical ComparisonAbout FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.